BioMarin said it is integrating Amicus Therapeutics after closing its $4.8 billion acquisition and plans layoffs tied to overlapping functions at the Amicus headquarters in Princeton, New Jersey. A WARN filing indicates 58 roles will be removed starting in August, with terminations targeted to end around late October. The company framed the integration as a scale-and-capabilities move to extend Amicus’ Fabry and Pompe medicines globally and to build on the acquired late-stage pipeline, including the phase 3 program for DMX-200 in focal segmental glomerulosclerosis (FSGS). BioMarin emphasized continuity for Amicus patients while aligning organizations for long-term execution.